Processing difficulties and instability of carbohydrate microneedle arrays

R. F. Donnelly, D. I. J. Morrow, T. R. R. Singh, K. Migalska, Paul McCarron, C. O'Mahony, A. D. Woolfson

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Background: A number of reports have suggested that many of the problems currently associated with the use of microneedle (MN) arrays for transdermal drug delivery could be addressed by using drug-loaded MN arrays prepared by moulding hot melts of carbohydrate materials. Methods: In this study, we explored the processing, handling, and storage of MN arrays prepared from galactose with a view to clinical application. Results: Galactose required a high processing temperature (160 degrees C), and molten galactose was difficult to work with. Substantial losses of the model drugs 5-aminolevulinic acid ( ALA) and bovine serum albumin were incurred during processing. While relatively small forces caused significant reductions in MN height when applied to an aluminium block, this was not observed during their relatively facile insertion into heat-stripped epidermis. Drug release experiments using ALA-loaded MN arrays revealed that less than 0.05% of the total drug loading was released across a model silicone membrane. Similarly, only low amounts of ALA ( approximately 0.13%) and undetectable amounts of bovine serum albumin were delivered when galactose arrays were combined with aqueous vehicles. Microscopic inspection of the membrane following release studies revealed that no holes could be observed in the membrane, indicating that the partially dissolved galactose sealed the MN-induced holes, thus limiting drug delivery. Indeed, depth penetration studies into excised porcine skin revealed that there was no significant increase in ALA delivery using galactose MN arrays, compared to control (P value < 0.05). Galactose MNs were unstable at ambient relative humidities and became adhesive. Conclusion: The processing difficulties and instability encountered in this study are likely to preclude successful clinical application of carbohydrate MNs. The findings of this study are of particular importance to those in the pharmaceutical industry involved in the design and formulation of transdermal drug delivery systems based on dissolving MN arrays. It is hoped that we have illustrated conclusively the difficulties inherent in the processing and storage of carbohydrate-based dissolving MNs and that those in the industry will now follow alternative approaches.
LanguageEnglish
Pages1242-1254
JournalDrug Development and Industrial Pharmacy
Volume35
Issue number10
DOIs
Publication statusPublished - 2009

Fingerprint

Galactose
Carbohydrates
Aminolevulinic Acid
Processing
Pharmaceutical Preparations
Bovine Serum Albumin
Membranes
Drug delivery
Drug Industry
Silicones
Drug Delivery Systems
Humidity
Aluminum
Epidermis
Molding
Adhesives
Molten materials
Industry
Atmospheric humidity
Skin

Cite this

Donnelly, R. F., Morrow, D. I. J., Singh, T. R. R., Migalska, K., McCarron, P., O'Mahony, C., & Woolfson, A. D. (2009). Processing difficulties and instability of carbohydrate microneedle arrays. Drug Development and Industrial Pharmacy, 35(10), 1242-1254. https://doi.org/10.1080/03639040902882280
Donnelly, R. F. ; Morrow, D. I. J. ; Singh, T. R. R. ; Migalska, K. ; McCarron, Paul ; O'Mahony, C. ; Woolfson, A. D. / Processing difficulties and instability of carbohydrate microneedle arrays. In: Drug Development and Industrial Pharmacy. 2009 ; Vol. 35, No. 10. pp. 1242-1254.
@article{97db58a520c94978969cc54d08fe97d1,
title = "Processing difficulties and instability of carbohydrate microneedle arrays",
abstract = "Background: A number of reports have suggested that many of the problems currently associated with the use of microneedle (MN) arrays for transdermal drug delivery could be addressed by using drug-loaded MN arrays prepared by moulding hot melts of carbohydrate materials. Methods: In this study, we explored the processing, handling, and storage of MN arrays prepared from galactose with a view to clinical application. Results: Galactose required a high processing temperature (160 degrees C), and molten galactose was difficult to work with. Substantial losses of the model drugs 5-aminolevulinic acid ( ALA) and bovine serum albumin were incurred during processing. While relatively small forces caused significant reductions in MN height when applied to an aluminium block, this was not observed during their relatively facile insertion into heat-stripped epidermis. Drug release experiments using ALA-loaded MN arrays revealed that less than 0.05{\%} of the total drug loading was released across a model silicone membrane. Similarly, only low amounts of ALA ( approximately 0.13{\%}) and undetectable amounts of bovine serum albumin were delivered when galactose arrays were combined with aqueous vehicles. Microscopic inspection of the membrane following release studies revealed that no holes could be observed in the membrane, indicating that the partially dissolved galactose sealed the MN-induced holes, thus limiting drug delivery. Indeed, depth penetration studies into excised porcine skin revealed that there was no significant increase in ALA delivery using galactose MN arrays, compared to control (P value < 0.05). Galactose MNs were unstable at ambient relative humidities and became adhesive. Conclusion: The processing difficulties and instability encountered in this study are likely to preclude successful clinical application of carbohydrate MNs. The findings of this study are of particular importance to those in the pharmaceutical industry involved in the design and formulation of transdermal drug delivery systems based on dissolving MN arrays. It is hoped that we have illustrated conclusively the difficulties inherent in the processing and storage of carbohydrate-based dissolving MNs and that those in the industry will now follow alternative approaches.",
author = "Donnelly, {R. F.} and Morrow, {D. I. J.} and Singh, {T. R. R.} and K. Migalska and Paul McCarron and C. O'Mahony and Woolfson, {A. D.}",
note = "PT: J; TC: 0",
year = "2009",
doi = "10.1080/03639040902882280",
language = "English",
volume = "35",
pages = "1242--1254",
journal = "Drug Development and Industrial Pharmacy",
issn = "0363-9045",
number = "10",

}

Donnelly, RF, Morrow, DIJ, Singh, TRR, Migalska, K, McCarron, P, O'Mahony, C & Woolfson, AD 2009, 'Processing difficulties and instability of carbohydrate microneedle arrays', Drug Development and Industrial Pharmacy, vol. 35, no. 10, pp. 1242-1254. https://doi.org/10.1080/03639040902882280

Processing difficulties and instability of carbohydrate microneedle arrays. / Donnelly, R. F.; Morrow, D. I. J.; Singh, T. R. R.; Migalska, K.; McCarron, Paul; O'Mahony, C.; Woolfson, A. D.

In: Drug Development and Industrial Pharmacy, Vol. 35, No. 10, 2009, p. 1242-1254.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Processing difficulties and instability of carbohydrate microneedle arrays

AU - Donnelly, R. F.

AU - Morrow, D. I. J.

AU - Singh, T. R. R.

AU - Migalska, K.

AU - McCarron, Paul

AU - O'Mahony, C.

AU - Woolfson, A. D.

N1 - PT: J; TC: 0

PY - 2009

Y1 - 2009

N2 - Background: A number of reports have suggested that many of the problems currently associated with the use of microneedle (MN) arrays for transdermal drug delivery could be addressed by using drug-loaded MN arrays prepared by moulding hot melts of carbohydrate materials. Methods: In this study, we explored the processing, handling, and storage of MN arrays prepared from galactose with a view to clinical application. Results: Galactose required a high processing temperature (160 degrees C), and molten galactose was difficult to work with. Substantial losses of the model drugs 5-aminolevulinic acid ( ALA) and bovine serum albumin were incurred during processing. While relatively small forces caused significant reductions in MN height when applied to an aluminium block, this was not observed during their relatively facile insertion into heat-stripped epidermis. Drug release experiments using ALA-loaded MN arrays revealed that less than 0.05% of the total drug loading was released across a model silicone membrane. Similarly, only low amounts of ALA ( approximately 0.13%) and undetectable amounts of bovine serum albumin were delivered when galactose arrays were combined with aqueous vehicles. Microscopic inspection of the membrane following release studies revealed that no holes could be observed in the membrane, indicating that the partially dissolved galactose sealed the MN-induced holes, thus limiting drug delivery. Indeed, depth penetration studies into excised porcine skin revealed that there was no significant increase in ALA delivery using galactose MN arrays, compared to control (P value < 0.05). Galactose MNs were unstable at ambient relative humidities and became adhesive. Conclusion: The processing difficulties and instability encountered in this study are likely to preclude successful clinical application of carbohydrate MNs. The findings of this study are of particular importance to those in the pharmaceutical industry involved in the design and formulation of transdermal drug delivery systems based on dissolving MN arrays. It is hoped that we have illustrated conclusively the difficulties inherent in the processing and storage of carbohydrate-based dissolving MNs and that those in the industry will now follow alternative approaches.

AB - Background: A number of reports have suggested that many of the problems currently associated with the use of microneedle (MN) arrays for transdermal drug delivery could be addressed by using drug-loaded MN arrays prepared by moulding hot melts of carbohydrate materials. Methods: In this study, we explored the processing, handling, and storage of MN arrays prepared from galactose with a view to clinical application. Results: Galactose required a high processing temperature (160 degrees C), and molten galactose was difficult to work with. Substantial losses of the model drugs 5-aminolevulinic acid ( ALA) and bovine serum albumin were incurred during processing. While relatively small forces caused significant reductions in MN height when applied to an aluminium block, this was not observed during their relatively facile insertion into heat-stripped epidermis. Drug release experiments using ALA-loaded MN arrays revealed that less than 0.05% of the total drug loading was released across a model silicone membrane. Similarly, only low amounts of ALA ( approximately 0.13%) and undetectable amounts of bovine serum albumin were delivered when galactose arrays were combined with aqueous vehicles. Microscopic inspection of the membrane following release studies revealed that no holes could be observed in the membrane, indicating that the partially dissolved galactose sealed the MN-induced holes, thus limiting drug delivery. Indeed, depth penetration studies into excised porcine skin revealed that there was no significant increase in ALA delivery using galactose MN arrays, compared to control (P value < 0.05). Galactose MNs were unstable at ambient relative humidities and became adhesive. Conclusion: The processing difficulties and instability encountered in this study are likely to preclude successful clinical application of carbohydrate MNs. The findings of this study are of particular importance to those in the pharmaceutical industry involved in the design and formulation of transdermal drug delivery systems based on dissolving MN arrays. It is hoped that we have illustrated conclusively the difficulties inherent in the processing and storage of carbohydrate-based dissolving MNs and that those in the industry will now follow alternative approaches.

U2 - 10.1080/03639040902882280

DO - 10.1080/03639040902882280

M3 - Article

VL - 35

SP - 1242

EP - 1254

JO - Drug Development and Industrial Pharmacy

T2 - Drug Development and Industrial Pharmacy

JF - Drug Development and Industrial Pharmacy

SN - 0363-9045

IS - 10

ER -